Clean Sweep Live Auction on Thur. March 28th. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
Current Location:
> This Story

Log in or Register to rate this News Story
Forward Printable StoryPrint Comment




Molecular Imaging Homepage

RadioMedix and Vect-Horus to develop brain theranostic agent for brain cancer Provide diagnosis and treatment of Glioblastoma Multiforme (GBM)

NIH awards $1.8 million to Magnetic Insight for neurovascular MPI Detects magnetic nanoparticle tracers, enables deep-tissue imaging

DOE to cut Moly-99 deals with four US firms Could be as much as $15 million per company, with partners matching awarded amounts

Women's brains appear three years younger than men's at the same age: PET study A machine-learning algorithm assisted with the analysis

Dennis Durmis MITA names chair of board of directors

Researchers find new PET tracer that better detects melanoma than 18F-FDG 18F-P3BZA could become the new gold standard

FDA clears United Imaging's total-body PET scanner Creating 3D images of entire human body in 15-30 seconds

FDA clears MIM SurePlan molecular radiotherapy software Can measure the absorbed dose from MRT for individual patients

Rob Beanlands ASNC names president for 2019

Former South African nuclear executives to appeal suspensions in court Involves monthslong shutdown of NTP Radioisotopes medical isotope plant

NIC has awarded RadioMedix $2 million
for the clinical development of

RadioMedix scores $2 million contract for Targeted Alpha-emitter therapy

by John R. Fischer , Staff Reporter
The National Cancer Institute, part of the National Institutes of Health, has granted RadioMedix a two-year, $2 million Phase II SBIR contract for the clinical development of its Targeted Alpha-emitter Therapy (TAT) for neuroendocrine tumors.

The award follows and is a continuation of the success of its Phase I SBIR contract around the use of 212Pb-octreotate analog (AlphaMedix) for patients with advanced neuroendocrine tumors (NETS) who have limited treatment options available to them.

Story Continues Below Advertisement

Has exclusive distribution agreement with DDD to sell new Camera systems

UMRi provides the very best new & refurbished gamma cameras, quality parts &repair services. We also rebuild & replace camera detectors, move camera systems across town or across the country. Call us at 888-239-3510

"Current approaches to cancer treatment are largely ineffective once the tumor has metastasized. Neuroendocrine tumors are rare, accounting for only 0.5% of all malignancies and their symptoms are usually vague and nonspecific," Izabela Tworowska, CSO of RadioMedix and the principal investigator of the SBIR Phase II contract, told HCB News. "Surgery is the principal therapy for localized disease however its success in advanced disease is limited. The combination chemotherapy used for management of NETs is associated with high toxicity and limited efficacy."

A heterogeneous group of rare neoplasms, neuroendocrine tumors stem from neuroendocrine cells and appear primarily in the gastrointestinal tract and pancreas, expressing somatostatin receptors. They can also occur in the thymus, lung and uncommon sites such as the cervix, heart and prostate.

AlphaMedix is a radiolabeled SSTR-targeting therapeutic investigation drug designed to treat NETs patients. Its composition consists of SSTR-targeting peptide complex radiolabeled with 212Pb, enabling it to act as a vivo generator of alpha-emitting particles. Its half-life, high energy, short path length of decay and irreversible damage to the double stranded DNA make it a well suited-source for SSTR therapy applications.

The Phase I clinical study was designed based on the results of the pre-clinical toxicity and efficacy studies performed with the scope of the NCI NIH Phase I Contract. The award builds on the progress made in this non-randomized, open-label, dose escalation study, with the NIH NCI Phase II Contract focused on determining the safety and pharmacokinetics of Pb212-octreotate (AlphaMedix) and selecting the effective doses for therapy of patients with somatostatin receptor positive neuroendocrine tumors.

"The recent FDA approval of 177Lu-DOTATATE (Lutathera, Advanced Accelerated Applications, currently Novartis) highlights the growth of the radiotherapeutic market. Despite this great success, there is a significant potential for improvement in safety, efficacy and lengthening progression free survival of patients by using targeted alpha emitter-therapy," said Tworowska. "Our hypothesis is that alpha emitters such as 212Pb with higher linear energy transfer (LET) and shorter path-length in tissue can deliver lethal dose to the tumor cells, causing permanent double strand DNA damage and less damage to the normal tissue. These characteristics should translate into the higher efficacy and safety of the treatment."

RadioMedix recently scored another award in the form of a fast-track designation by the FDA for 64-Cu-Dotatate, an investigational diagnostic radiopharmaceutical that it’s developing and commercializing alongside Curium.

The project is funded with federal funds from the National Cancer Institute, National Institutes of Health and the Department of Health and Human Services.

Clinical studies around the use of AlphaMedix are currently underway at the Excel Diagnostics and Nuclear Oncology Center in Houston.

Molecular Imaging Homepage

You Must Be Logged In To Post A Comment

Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Gold Service Dealer Program
Receive RFP/PS
Healthcare Providers
See all
HCP Tools
A Job
Parts Hunter +EasyPay
Get Parts
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.